Immediate postabortion initiation of levonorgestrel implants reduces the incidence of births and abortions at 2 years and beyond

被引:30
作者
Rose, Sally B. [1 ]
Garrett, Susan M. [2 ]
Stanley, James [3 ]
机构
[1] Univ Otago, Dept Primary Hlth Care & Gen Practice, Wellington 6242, New Zealand
[2] Univ Otago, Dept Primary Hlth Care & Gen Practice, Womens Hlth Res Ctr, Wellington 6242, New Zealand
[3] Univ Otago, Deans Dept, Biostat Grp, Wellington 6242, New Zealand
关键词
Copper multiload Cu375 intrauterine device; Levonorgestrel intrauterine system; Levonorgestrel-releasing subdermal implant; Long-acting reversible contraception (LARC); Unintended pregnancy; ACTING REVERSIBLE CONTRACEPTION; REPEAT PREGNANCY; NO-COST; CONTINUATION; WOMEN; TERMINATION;
D O I
10.1016/j.contraception.2015.03.012
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: The aims of this study were to compare immediate postabortion uptake of recently subsidized (no-cost) levonorgestrel-releasing implants with already available intrauterine and shorter-acting methods and to compare the incidence of subsequent pregnancies (ending in birth or abortion) within 2 years. Study design: Retrospective chart review of 4698 women attending a New Zealand public hospital abortion clinic over 2 years (2010-2012) to describe postabortion contraceptive choice, with follow-up via clinic and national births records to assess subsequent pregnancies at 12, 24, 36, and 48 months. Results: Twenty percent of the cohort (934/4698) received an implant, 26% an intrauterine method (927 copper intrauterine device, 301 levonorgestrel-releasing intrauterine system [LNG-IUS]), and 54% chose other shorter-acting methods (2536/4698). Method choice was significantly associated with age, ethnicity, and pregnancy history (p < .001). At 24 months, the unadjusted incidence of subsequent abortion for implant users was 3.8% (95% confidence interval [CI] = 2.5-5.0) and 11.6% (95% CI = 10.3-12.8) for those choosing other short-acting methods. By 48 months, 6.6% of implant users had a subsequent abortion (compared with 18.3% for short-acting methods). The incidence of continued pregnancy at 24 months was 6.3% (95% CI = 4.4-8.1) for implant users and 15.7% (95% CI = 14-17.2) for those choosing other short-acting methods. Adjusted hazard ratios (BRs) for subsequent abortion were lowest for women initiating an implant (BR = 0.26, 95% CI = 0.20-0.35) or LNG-IUS (BR = 0.26, 0.16-0.44, reference group: short-acting methods). Conclusions: Immediate postabortion insertion of an implant significantly reduced rates of subsequent pregnancy for at least 2 years. Abortion service providers should ensure women have barrier-free access to all long-acting reversible contraceptions to delay or prevent pregnancy. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:17 / 25
页数:9
相关论文
共 30 条
[1]   Preventing repeat abortion in Canada: is the immediate insertion of intrauterine devices postabortion a cost-effective option associated with fewer repeat abortions? [J].
Ames, Christina M. ;
Norman, Wendy V. .
CONTRACEPTION, 2012, 85 (01) :51-55
[2]  
[Anonymous], ETHN DAT PROT HLTH D
[3]   The Effect of Long-Acting Reversible Contraception on Rapid Repeat Pregnancy in Adolescents: A Review [J].
Baldwin, Maureen K. ;
Edelman, Alison B. .
JOURNAL OF ADOLESCENT HEALTH, 2013, 52 (04) :S47-S53
[4]   Effect of contraception provided at termination of pregnancy and incidence of subsequent termination of pregnancy [J].
Cameron, S. T. ;
Glasier, A. ;
Chen, Z. E. ;
Johnstone, A. ;
Dunlop, C. ;
Heller, R. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2012, 119 (09) :1074-1080
[5]   Postabortal and postpartum contraception [J].
Cameron, Sharon .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2014, 28 (06) :871-880
[6]  
Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, 2012, AD LONG ACT REV CONT, P539
[7]   Cost as a Barrier to Long-Acting Reversible Contraceptive (LARC) Use in Adolescents [J].
Eisenberg, David ;
McNicholas, Colleen ;
Peipert, Jeffrey F. .
JOURNAL OF ADOLESCENT HEALTH, 2013, 52 (04) :S59-S63
[8]  
GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
[9]  
Hatcher RobertAnthony., 2011, CONTRACEPTIVE TECHNO
[10]  
Kleinbaum DG, 2012, STAT BIOL HEALTH, P1, DOI 10.1007/978-1-4419-6646-9